Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

The early results for stop-loss claims, or claims for catastrophic losses, are in line with the insurer's expectations, ...

With more than 3,500 students, Brockton High School is the biggest high school in Massachusetts and become known in recent years for chronic understaffing. Mirroring the nickname of its sports teams, ...

Mass Gen's Dr. Ali Raja explains why some were sent to the emergency room after using semaglutide injections. Raja says some of the symptoms people experienced won't require an ER visit. Raja says not ...

Obesity rates in the U.S. are rising, with 2 in 5 adults affected. This leads to health issues, economic costs, and raises ...

Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer.

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

The US Food and Drug Administration (FDA) accepted Novo Nordisk’s New Drug Application (NDA) submission for an ...